1、FY 2024 resultsMarch 5,20252This presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis of managements views and assumptions regarding future events and business performance at the time the statements are mad

2、e.They are subject to risks and uncertainties including,but not confined to,future global economic conditions,exchange rates,legal provisions,market conditions,activities by competitors and other factors outside of the control of Sandoz.Should one or more of these risks or uncertainties materialize

3、or should underlying assumptions prove incorrect,actual outcomes may vary materially from those forecasted or expected.Each forward-looking statement speaks only as of the date of the particular statement,and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements

4、,except as required by law.This presentation includes non-IFRS financial measures as defined by Sandoz.An explanation of non-IFRS measures can be found in the supplementary financial information of the Integrated Annual Report 2024.Disclaimer3Agenda1.Highlights2.Business update3.Financial performanc

5、e4.Full-year 2025 guidance&mid-term outlook5.Wrap-up1.Highlights511.FY 2024,in constant currencies 2.Subject to approval at the Annual General Meeting on April 15,2025On track to deliver on our commitmentsDriving top lineAdvancingon pipelineCreating value USD 10 billion in net sales for the first ti

6、me 30%1 biosimilar growth All regions contributing to growth Three regulatory approvals and three launches Pipeline expanded to 28 biosimilars Numerous opportunities to increase coverage Core ROIC up 2.5%pts to 12.3%Dividend increase to CHF 0.60 per share2 Investing in growth opportunitiesExpanding